Literature DB >> 8516381

Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium.

C Guarnieri1, C Muscari.   

Abstract

The mitochondria harvested at the end of perfusion of control hearts and assayed for respiratory activity had a better function after ischemia and reperfusion following trimetazidine injection when glutamate was used as substrate. The protective effect of trimetazidine was enhanced when the mitochondria were isolated from hypertrophied perfused rat hearts. In fact the drug improved both the RCI and QO2 parameters with glutamate or succinate as substrates and raised the glutamate-induced QO2 value of mitochondria extracted from the hypertrophied heart perfused in aerobic conditions. In the aerobically perfused heart trimetazidine did not change either the levels of tissue malondialdehyde and lipofuscin, or the rate of mitochondrial O.2 generation while it reduced the O.2 formation and malondialdehyde content in the hypertrophied heart. After ischemia and reperfusion, the drug reproduced these protective effects in the hypertrophied hearts and reduced the level of tissue malondialdehyde in control hearts. The protective effect of trimetazidine against MDA formation was dose-dependent, being more evident at a higher dose (10 mumol/l). Preincubation of rat heart mitochondria with 0.1-10 mumol/l trimetazidine did not affect NADH oxidase, NADH dehydrogenase and NADH-cytochrome c reductase, succinate oxidase and cytochrome c oxidase activities. These results indicate that trimetazidine injected into isolated rat hearts protects against the damage induced on cardiac energetics and oxidative injuries by moderate ischemia and reperfusion stress, particularly in monocrotaline-induced hypertrophy in the rat heart. We suggest that trimetazidine reduces the formation of oxidative damage by preserving cardiac mitochondrial function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8516381     DOI: 10.1159/000139070

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  16 in total

1.  [(3)H]-trimetazidine mitochondrial binding sites: regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance.

Authors:  D Morin; R Sapena; A Elimadi; B Testa; S Labidalle; A Le Ridant; J P Tillement
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

2.  Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.

Authors:  Hagir B Suliman; Eva Nozik-Grayck
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

Review 3.  Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.

Authors:  Victor Soukoulis; William E Boden; Sidney C Smith; Patrick T O'Gara
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

4.  Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy.

Authors:  P Di Napoli; A A Taccardi; A Barsotti
Journal:  Heart       Date:  2005-02       Impact factor: 5.994

Review 5.  Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.

Authors:  K J McClellan; G L Plosker
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

6.  Anticonvulsant and antioxidant actions of trimetazidine in pentylenetetrazole-induced kindling model in mice.

Authors:  Seema Jain; Nidhi Bharal; Sonam Khurana; Pramod Kumari Mediratta; Krishna Kishore Sharma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-12       Impact factor: 3.000

7.  Energy metabolism and mechanical recovery after cardioplegia in moderately hypertrophied rats.

Authors:  R T Smolenski; J Jayakumar; A M Seymour; M H Yacoub
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

8.  Trimetazidine protects against hypoxia-reperfusion-induced cardiomyocyte apoptosis by increasing microRNA-21 expression.

Authors:  Qiong Yang; Kan Yang; An-Ying Li
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

9.  The acute administration of trimetazidine modified myocardial perfusion and left ventricular function in 31 patients with ischaemic ventricular dysfunction.

Authors:  Mauro Feola; Alberto Biggi; Antonella Francini; Giovanni Leonardi; Flavio Ribichini; Valeria Ferrero; Eugenio Uslenghi
Journal:  Int J Cardiovasc Imaging       Date:  2004-08       Impact factor: 2.357

10.  Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression.

Authors:  Sheik Wisel; Mahmood Khan; M Lakshmi Kuppusamy; I Krishna Mohan; Simi M Chacko; Brian K Rivera; Benjamin C Sun; Kálmán Hideg; Periannan Kuppusamy
Journal:  J Pharmacol Exp Ther       Date:  2009-02-13       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.